Use of sustained release antibiotic compositions in ophthalmic surgical procedures
AssigneeAlcon Laboratories, Inc.
InventorsGerald D. Cagle, Tai-Lee Ke, Barry A. Schlech, Ole J. Lorenzetti
Life of this patent
Estimating the term…
Abstract
An improved method of sterilizing the field of surgery prior to an ophthalmic surgical procedure is described. The invention eliminates the need for painful and potentially traumatic injections of antibiotics by utilizing sustained release compositions which allow the antibiotics contained therein to penetrate deeply into the eye, thereby ensuring a sterile field of surgery during intraocular surgical procedures. The compositions may also be utilized to prevent post-surgical infections.
Claims4
A topical ophthalmic composition for sterilizing the ophthalmic tissues of a human or animal patient in the area of surgery prior to an ophthalmic surgical procedure or prophylactically treating bacterial infections of the eye resulting from the ophthalmic surgical procedure, comprising:
- an antimicrobial effective amount of ciprofloxacin;
- a carboxy vinyl polymer having a molecular weight of 50,000 to 6,000,000;
- and
- 0.01 to 1.0 wt. % of dodecylmaltoside.
A method of sterilizing the ophthalmic tissues of a human patient in the area of surgery prior to an ophthalmic surgical procedure, which comprises topically applying to the affected eye prior to the surgical procedure a single dose of an ophthalmic composition comprising:
- an antimicrobial effective mount of ciprofloxacin;
- a carboxy vinyl polymer having a molecular weight of 50,000 to 6,000,000;
- and
- 0.01 to 1.0 wt. % of dodecylmaltoside.
A method of prophylactically treating ocular bacterial infections resulting from an ocular surgical procedure in a human or animal patient, which comprises topically applying to an eye of the patient which has undergone a surgical procedure a single dose of a composition comprising:
- an antimicrobial effective amount of ciprofloxacin;
- a carboxy vinyl polymer having a molecular weight of 50,000 to 6,000,000;
- and
- 0.01 to 1.0 wt. % of dodecylmaltoside.
Dependencies are inferred from the claim text.